← Back to Search

CAR T-cell Therapy

VCAR33 for Leukemia

Phase 1 & 2
Recruiting
Research Sponsored by Vor Biopharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new therapy that uses cells from a donor to treat relapsed/refractory leukemia after an allogeneic transplant.

Who is the study for?
Adults with Acute Myeloid Leukemia that has returned or resisted treatment after a specific type of bone marrow transplant (HLA-matched alloHCT) can join. They must have received the transplant from a donor who matches them on eight key genetic markers and is willing to undergo a procedure for this trial. Patients should be in good physical condition, with their major organs functioning well.
What is being tested?
The trial is testing VCAR33, which is a new therapy involving T cells (a type of immune cell) engineered to target leukemia cells in patients whose AML has come back or hasn't responded after receiving an HLA-matched alloHCT. It's an early-stage trial to see how safe it is and how well it works.
What are the potential side effects?
Potential side effects may include reactions related to the immune system attacking normal cells, symptoms at the infusion site, tiredness, fever, chills, breathing difficulties, changes in blood pressure and heart rate. The exact side effects will be monitored closely due to the novel nature of this therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: Morphologic Disease: Cohort 3Experimental Treatment1 Intervention
VCAR33 Dose Level 3
Group II: Morphologic Disease: Cohort 2Experimental Treatment1 Intervention
VCAR33 Dose Level 2
Group III: Morphologic Disease: Cohort 1Experimental Treatment1 Intervention
VCAR33 Dose Level 1
Group IV: MRD Positive: Cohort 3Experimental Treatment1 Intervention
VCAR33 Dose Level 3
Group V: MRD Positive: Cohort 2Experimental Treatment1 Intervention
VCAR33 Dose Level 2
Group VI: MRD Positive: Cohort 1Experimental Treatment1 Intervention
VCAR33 Dose Level 1

Find a Location

Who is running the clinical trial?

Vor BiopharmaLead Sponsor
2 Previous Clinical Trials
60 Total Patients Enrolled

Media Library

VCAR33 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05984199 — Phase 1 & 2
Acute Myeloid Leukemia Research Study Groups: Morphologic Disease: Cohort 1, MRD Positive: Cohort 3, MRD Positive: Cohort 1, Morphologic Disease: Cohort 3, MRD Positive: Cohort 2, Morphologic Disease: Cohort 2
Acute Myeloid Leukemia Clinical Trial 2023: VCAR33 Highlights & Side Effects. Trial Name: NCT05984199 — Phase 1 & 2
VCAR33 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05984199 — Phase 1 & 2
~12 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top